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36 (-9.50 [-10.97, -8.04; P< 0.0001], n= 584). PRIMUS ALS scores also improved from 
baseline (mean change [95% CI]) to Week 12 (-2.47 [-2.83, -2.11; P< 0.0001], n= 501) 
and Week 36 (-1.53 [-1.96, -1.10; P< 0.0001], n= 437) in patients on treatment. Results 
for the change from baseline to Week 48 for outcomes, including the SF-36 PCS, in 
patients on treatment will be presented. ConClusions: PR-fampridine, which 
improves walking in MS, shows benefits on HRQoL through 36 weeks of treatment.
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objeCtives: The current prevalence of Multiple Sclerosis (MS) in Slovakia ranges 
from 100 till 150 cases per 100 000 population Being a typical chronic disease 
with tendency of progression, MS can have a great impact on quality of life (QoL). 
The objective of this paper was to find out the level of QoL in patients with MS in 
Slovakia. Methods: The primary method used for the analysis of QoL was the 
presence of disability period and combined questionnaire consisting of 4 parts: 
A. Demography and socioeconomics (13 items), B. Generic questionnaire (SF-36), 
C. Visual scale (4 items), D. Complementary (information and habits, 13 items). There 
were 2 groups of patients. Group A: 41 (29 women, 12 men) patients were treated by 
conventional therapy. Group B: the 41 (32 women, 9 men) patients were treated by 
moderns disease modifying treatment and biological therapy (Betaferon, Avonex, 
Rebif, Tysabri, Gilenya, Copaxone). The average age in the group A was 50.59 vs 
41.82 years in the group B. Results: Disability was 9,39 months per one patient 
per year in group A vs 5,02 in group B, loss of income was 123 vs 165 € per person, 
the expectations of the future was 2,39 vs 2,41 (in the five degrees scale). Present 
level of QoL was identified as 5.29 vs 4,34 on the scale of 10, while in the time of the 
MS diagnosis it was 3,29 vs 2,15. QoL was 8.68 vs 8,17 in the time without SM and 
9,24 vs 8,29 in the total optimal state of health. ConClusions: The treatment of 
MS by conventional or disease modifying therapy (DMT) had a significant impact 
on QoL. The modern DMT had the higher statistical influence as on physical health 
(45,65 vs 28,23) so on mental health (51,65 vs 33,01) in comparison with the patients 
treated by conventional therapy.
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objeCtives: To determine the correlation between the Montgomery-Asberg 
Depression Rating Scale (MADRS) and the Beck Depression Inventory II (BDI-II) 
scores in patients with drug-resistant focal epilepsy (DRE) in comparison with 
patients with controlled focal epilepsy (CFE). Methods: Observational, cross-
sectional study performed in patients with focal epilepsy (FE) with and without 
DRE, ≥ 18 years. Presence and severity of depression were measured using validated 
Spanish versions of the Montgomery-Asberg Depression Rating Scale (MADRS) and 
the Beck Depression Inventory (BDI-II). In order to know the correlation between 
MADRS and BDI-II, two different criteria were used; degree of association obtained 
on prevalence of depression and correlation between scores from both scales, using 
Pearson correlation coefficient. Results: 515 patients (DRE= 248) were included. 
Using the MADRS scale, prevalence of depression in the DRE group was almost 
double than in the CFE group (59.3% vs. 30.3% using unadjusted data and 62.1% vs. 
32.6% using adjusted data; p< 0.001). Similar results were seen with the BDI, with 
an overall depression rate of 48.1% using the ≥ 10 point threshold, and considerably 
higher rates of depression in the DRE group compared to CFE patients (61.9 % vs. 
35.3% using unadjusted data, and 64.8% vs. 37.2% using adjusted data; p< 0.001). 
Correlation between MADRS and BDI-II was 24,4 % (65/266) in CFE and 51,0% 
(126/247) in DRE patients, according to the degree of association; while the Pearson 
correlation coefficient between the two scales was high, at r= 0.80. ConClusions: 
MADRS and BDI-II showed a positive correlation; the score increment of one scale 
is directly proportional to the increase of the other scale. In both cases, the strong-
est contributor to higher MADRS and BDI-II scores was having a previous clinical 
diagnosis of depression but being untreated for the condition.
Neurological DisorDers – health care use & Policy studies
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objeCtives: After the introduction of the new German law AMNOG a statistically 
significant and clinically meaningful difference in patient relevant endpoints are 
required in order to achieve a (significant) clinical benefit for a new (drug) ther-
apy. The question remains if such an incentive is sufficient in all disease areas 
for positive investment decisions for the pharmaceutical industry. Methods: In 
Parkinson’s disease motor fluctuations and dyskinesias are two major patient rel-
evant outcomes. Different target profiles for a clinical development programme 
of a theoretical new treatment were developed including scenarios following the 
regulatory guidelines only, an efficacy-driven programme and one including the 
above mentioned key patient relevant endpoints. An investment decision model was 
developed based on these profiles with respect to additional clinical benefit by the 
joint federal committee and premium pricing in Germany were assessed. Results: 
Positive investment decisions were possible for the regulatory and efficacy-driven 
objeCtives: DMTs constitute an important backbone of MS treatment. To inves-
tigate Health Related Quality of Life (HRQOL) and patient adherence rates to the 
approved DMTs for RRMS among geographically and culturally diverse patient 
populations, a multinational study was to be implemented. Operational and sci-
entific outcomes are presented. Methods: The study was designed as an obser-
vational, multicenter, multinational post marketing study. Patients and physicians 
received paper questionnaires evaluating adherence to DMTs approved at the time 
of the study. HRQOL (MusiQol) and a Neuropsychological Questionnaire (MSNQ) 
also were applied. Results: The study was implemented in 22 countries. Special 
challenges: cross-cultural CRF design, country-specific recruitment procedures for 
sites and patients, country/site specific contractual arrangements. Ethical approval 
was collected from 70 local and 15 central institutions. Patient recruitment was 
performed via 176 neurologists (hospital and office based). In total, 2.566 patients 
were enrolled within 6 months. Average treatment duration / observational period 
covered 31 months. The study findings revealed that 75% of the patients were adher-
ent (i.e. not missing an injection or changing dose). 12.6% of all patients forgot to 
administer injections compared to 50% of non-adherent patients. Compared to 
non-adherent patients, adherent patients showed shorter disease duration (adher-
ent: median 6.0 yrs; non-adherent: Median 7.0 yrs.), significant shorter treatment 
time (30.0 months vs. 36.0 months; p< 0,001) and a better MSNQ score (18.0 vs. 22.0; 
p< 0,001). ConClusions: For implementing a global multicenter center impor-
tant issues include: linguistic specifics for CRF development, availability of medical 
centers for site recruitment, country specific legal and ethical requirements, care-
ful organization and sharing of responsibilities between the study coordination 
center and local affiliates. Non-adherence to DMT in RRMS was demonstrated to 
be mainly caused by injection problems; adherent patients showed better clinical 
and HRQOL outcomes.
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objeCtives: To examine the quality of life (QoL) of the Alzheimer’s Disease (AD) 
patients in relation to disease progression during the five-year ALSOVA follow-up 
study. Methods: The baseline sample consisted of 240 subjects with very mild 
or mild AD, 65 years or older, from three Finnish hospital districts. The subjects 
were recruited between 2002 and 2006, and were followed-up for five years. Three 
separate patient-reported wellbeing and life satisfaction instruments were used as 
proxy variables for QoL: a generic, preference-based health-related quality-of-life 
instrument, 15D; an AD -specific wellbeing measure, AD-QOL; and a VAS-based 
life satisfaction scale. AD progression was evaluated with the Clinical Dementia 
Rating (CDR). Both CDR Sum-of-Boxes (CDR-SOB) and global rating were used in the 
analysis. Generalized linear mixed models with hierarchical structure were applied 
to account for repeated measures and possible clustering by the hospital district. 
Data were adjusted for age, sex and years of education. Results: On average, none 
of the three outcome measures demonstrated statistically significant changes over 
time during the five year follow-up. However, when the outcomes were examined 
in relation to AD progression, both CDR-SOB and CDR global rating demonstrated 
statistically significant association between the severity of AD and lower QoL on all 
three outcome measures. However, when using CDR global rating to define disease 
progression, we observed meaningful impairments in QoL variables only in the 
patients with severe AD (CDR 3). ConClusions: Severe AD has a considerable 
impact on patients’ QOL through substantial impairments in wellbeing and life 
satisfaction. Evidence suggest that CDR-SOB is a potential continuous measure of 
AD severity. While CDR-SOB is strongly associated with decrease QoL measures, our 
observations indicate that it is unlikely to be linearly correlated with QoL. Thus, the 
use of CDR-SOB as a determinant of QoL needs to be examined further.
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objeCtives: Prolonged-release (PR) fampridine tablets (dalfampridine extended 
release in US) improve walking in some patients with multiple sclerosis (MS). The 
ENABLE study assessed the effect of long-term PR-fampridine treatment on health-
related quality of life (HRQoL) in MS patients with walking impairment. Methods: 
ENABLE is an open-label, 48-week study to evaluate the effect of PR-fampridine 10 
mg twice daily on HRQoL in MS patients. Patients completed the Timed 25-Foot 
Walk (T25FW) at baseline and Weeks 2 and 4, and the 12-item MS Walking Scale 
(MSWS-12) at baseline and Week 4. Patients with any improvement in T25FW 
speed at both Weeks 2 and 4, and any improvement in MSWS-12 score at Week 
4 remained on treatment. HRQoL measures are assessed at baseline and Weeks 
12, 24, 36, and 48, and include the Short-Form Health Survey (SF-36), Multiple 
Sclerosis Impact Scale (MSIS-29), and the Patient Reported Indices for MS Activity 
Limitations Scale (PRIMUS ALS). The primary endpoint is the change from baseline 
in the SF-36 physical component summary (PCS) score at each visit in patients on 
treatment. Results: At Week 4, 704 patients (78.1% of total enrollment [N= 901]) 
met the criteria to remain on treatment. Interim results at 36 weeks in patients 
on treatment show improvement from baseline (mean change [95% CI]) in MSIS-
29 Physical scores to Week 12 (-12.99 [-14.24, -11.74; P< 0.0001], n= 672) and Week 
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A multi-center retrospective chart-review study of MS patients conducted in United 
Kingdom (UK), France (FR), Germany (DE), Italy (IT), Spain (SP) and US to collect 
de-identified data on diagnosis, clinical status and DM approaches. Health care 
providers (HCPs; 95% neurologists) were screened for duration of practice (> = 3yrs) 
and patient volume (> = 15 MS patients/month) and recruited from a large panel to be 
geographically representative in each country. Medical charts of next 10 consecutive 
MS patients were selected by each physician. Results: A total of 3490 eligible MS 
patient charts were abstracted by 360 HCPs (mean age:47yrs; female: 31%; mean 
practice duration:18yrs; mean # of patients seen per month:63; % working in spe-
cialty MS clinic:45%). Patient mean age: 39yrs; female: 66%; top-5 comorbidities: 
depression (14%), anxiety (10%), hypertension (8%), obesity (7%), migraine/headache 
(6%). Tests used by physicians to diagnose MS varied between the countries (UK/
FR/DE/IT/SP/US: %): History/Neurological exam – 79/88/99/95/97/88, Gadolinium 
MRI – 56/93/66/93/96/89, T1 MRI – 49/89/80/84/93/74, T2 MRI – 65/89/66/91/94/82, 
CSF analysis – 51/82/71/3/90/56, Evoked potentials – 34/48/65/77/80/29. Patients 
with moderate/severe disease and currently on disease modifying treatments 
(DMTs) varied (UK/FR/DE/IT/SP/US: %): 50/45/37/58/50/47 & 52/71/75/77/73/78; cor-
respondingly, tests used by physicians to assess MS disease progression/activity 
also varied between the countries (UK/FR/DE/IT/SP/US: %): EDSS–63/83/84/91/92/40, 
Neurological exam–81/91/88/89/84/86, Gadolinium MRI–33/69/36/90/68/70, T1 MRI–
21/53/53/76/54/54, T2 MRI–29/62/41/89/63/65, Ambulation index–9/13/9/24/16/19, 
Brain atrophy–4/14/6/23/15/18, Nine hole peg test–6/3/10/5/3/1 and PASAT–
1/0/12/5/4/1. ConClusions: UK physicians appear to under-utilize the tests to 
diagnose/manage MS patients, whereas physicians in Spain often used them more 
frequently. Observed trends were not correlated to the patient disease severity 
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objeCtives: Differences in compliance and persistence between Parkinson’s dis-
ease (PD) drugs were found in a previous US claim database analysis. The objective 
was to apply the same methodology in another setting using the Clinical Practice 
Research Datalink (CPRD) in the UK. Methods: A retrospective analysis of patients 
starting a new PD drug (rasagiline, selegiline, pramipexole, ropinirole, entacapone, 
tolcapone, levodopa) between January 2009 and January 2012 was conducted using 
CPRD. Patients were categorized as naive to PD therapy (NT) or having prior PD 
therapy (PT), depending on the prescription of other PD drugs within a 12-month 
look-back period. The observation period was 12 months. Compliance was measured 
using the medication possession ratio (MPR) and non-compliance was defined as 
an MPR≤ 80%. Persistence was measured as the duration (days) of uninterrupted 
therapy without gap higher than 45 days. Results: Of the 4,784 patients included 
in the compliance analysis, 3,675 patients (76.8%) had compliance rates > 80%. Mean 
MPRs were generally comparable across PD products (range:84%-90%, all pairwise 
p= NS). Percentage of patients with MPR> 80% was significantly greater with rasagil-
ine (85.6%, all p< 0.05 except vs. ropinirole p= NS). Of the 5,266 patients included in 
the persistence analysis, the highest mean number of persistent days of treatment 
was reported for rasagiline (284 days; all p< 0.05 vs others, except vs. ropinirole 
p= 0.14 and levodopa p= 0.06). Patient persistence at 12 months was significantly 
greater with rasagiline compared with others in NT patients (66.5%, all p< 0.05) 
scenarios even though that the additional clinical benefit profile was uncertain and 
pricing not optimal. When developing potential budget estimates based on sample 
size and complexity of a clinical trial for motor fluctuations or dyskinesias as pri-
mary endpoint a significant clinical benefit was highly likely and premium pricing 
possible. However, a positive investment decision was uncertain due to the high 
development cost. ConClusions: Even though there are incentives to add patient 
relevant endpoints in the development programmes the return on investment could 
potentially not be high enough for a positive investment decision. Target profiling 
including market access and pricing outcomes could optimize investment decisions.
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objeCtives: To assess clinical characteristics of MS patients not on any DMTs in key 
countries in European Union (EU) and the U.S. Methods: A multi-country multi-
center medical chart-review study of MS patients was conducted in 4Q2012 among 
Health care providers (HCPs; > 85% neurologists) in hospitals and private practices 
to collect de-identified data. HCPs from UK, Germany, France, Italy and Spain (5EU) 
and the US were screened for duration of practice (> = 3yrs) and patient volume 
(> = 15 MS patients/month) and recruited from a large panel to be geographically 
representative in each country. Medical charts of next 10 consecutive MS patients 
were completed by each physician. HCPs abstracted patient diagnosis, treatment 
patterns and patient symptomatology/disease status. MS patients not on any 
DMTs were analyzed. Results: A total of 967 eligible MS patients were included 
in the analysis (5EU:749; US:218). Mean age (yrs) – 5EU:39.0yrs, US:42.2yrs; Female – 
5EU:69%; US:67%. Key reasons for not receiving DMTs were (5EU/US): mild/early-MS 
(35%/36%), patient refusal (26%/44%), progressive/severe/advanced-MS (20%/17%), 
lack of efficacy of current treatment options (10%/14%), side-effects/tolerance/co-
morbidities (6%/12%), waiting for DMTs to become available (5%/12%) and funding/
authorization/guidelines (4%/7%). Among patients who refused DMTs, more than 
half were not convinced of therapy benefits. Distribution of MS type was (5EU/US): 
Clinically Isolated Syndrome (CIS)-26%/25%, Relapse Remitting MS (RRMS)-44%/49% 
and Secondary Progressive MS (SPMS)-30%/26%. Patients with moderate/severe dis-
ease and those with active/highly active disease (both, per physician judgment) 
were (5EU/US): CIS:10%/11%, RRMS:25%/40%, SPMS:95%/86%, and CIS:31%/44%, 
RRMS:39%/37%, SPMS:36%/32% respectively. Mean Expanded Disability Status Scale 
score were (5EU/US): CIS:0.8/0.7, RRMS:1.8/2.2, SPMS:6.5/5.6); % patients currently 
suffering a relapse were (5EU/US): CIS:20%/29%, RRMS:21%/15%, SPMS:6%/16%; 
% patients with > = 1 relapses in last 12months were (5EU/US): CIS:69%/69%, 
RRMS:52%/58%, SPMS:18%/32%. ConClusions: Among MS patients not on any 
DMTs, disease burden seems substantial. Further research is warranted to scrutinize 
the observed patient management practices to alleviate patient burden.
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objeCtives: To assess disease burden of SPMS patients treated with DMTs in 
EU and the U.S. Methods: A multi-country chart-review study of SPMS patients 
was conducted among neurologists in hospitals/private practices to collect de-
identified data. Neurologists from UK/Germany/France/Italy/Spain (5EU) and 
US were screened for practice-duration (> = 3yrs) and patient-volume (> = 15MS 
patients/month) and recruited from a large panel to be geographically representa-
tive in each country. Charts of next 2 consecutive SPMS patients were selected 
by each neurologist. Neurologists abstracted patient diagnosis, treatment pat-
terns and patient symptomatology/disease status. SPMS patients on DMTs were 
analyzed. Results: In 4Q2012, 360 Neurologists (5EU:259; US:101) abstracted 699 
eligible SPMS patient charts (5EU:497; US:202); 420 (5EU:274; US:146) patients were 
managed with DMTs. Mean age – 5EU:46.5yrs, US:49.2yrs; Female – 5EU:58%; US:66%. 
Mean time-to-1st DMT initiation (5EU/US; months) from diagnosis was 21/27; cur-
rent DMT patterns (5EU/US) were: 1st line (25%/34%), 2nd line (39%/38%) & 3rd+ 
line (36%/28%). Interferon beta-1b (5EU) and glatiramer acetate (US) were predomi-
nantly observed in 1st/2nd line; fingolimod and natalizumab use was observed 
in 2nd-line but they dominated later lines. Mean time-to-1stDMT initiation (5EU/
US: months) from diagnosis (1st:45/35, 2nd:13/30, 3rd+:12/10) and mean treatment 
time (5EU/US: months) on current 1st (85/91), 2nd (38/35; prior 1st line: 57/48) and 
3rd+ line (19/24; prior 2nd line: 35/46) differed. Patients with severe disease and 
those with active/highly active disease (both, per physician judgment) were (5EU/
US): 1st:15%/20%, 2nd:20%/18%, 3rd+:35%/37% and 1st:45%/61%, 2nd:63%/73%, 
3rd+:57%/68% respectively; mean Expanded Disability Status Scale scores also dif-
fered (5EU/US): 1st:5.1/5.0, 2nd:5.6/5.5, 3rd+:5.8/6.1. ConClusions: Among SPMS 
patients currently managed with DMTs, the disease burden increased as the line 
of treatment increased, both in 5EU and the US. Patients in 2nd/3rd+line of treat-
ments had progressed through earlier line(s) of treatment quickly. Further research 
is warranted to scrutinize the effectiveness of therapeutic options and sequencing 
strategies to alleviate patient burden.
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objeCtives: To assess the patterns of use of tests to diagnose and assess disease 
progression/activity in MS in the European Union and United States (US). Methods: 
